It’s been an up-and-down week for the Coalition for Affordable Drugs, hedge fund manager Kyle Bass and serial patent litigant Erich Spangenberg’s campaign to convince the U.S. Patent and Trademark Office to invalidate select patents on pricey prescription drugs. The agency denied three of the coalition’s petitions on Thursday, just three days after it agreed to review two other petitions.
In three separate decisions, the PTO’s Patent Trial and Appeal Board denied three challenges the coalition lodged against patents for the pain medication Subsys, owned by Insys Pharma Inc. The medication is a sublingual spray that helps patients manage constant cancer pain.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
